Home Analyst Ratings Daiwa initiates Amgen Inc. (AMGN) at buy and sets price target at...

Daiwa initiates Amgen Inc. (AMGN) at buy and sets price target at $300

Daiwa launched its Amgen Inc. [NASDAQ:AMGN]‎ rating to the equivalent of Buy and assigned ‎the ‎price target of $300, in a ‎research note dated December 29, 2020. That figure represents around a ‎‎25.45% premium ‎from where ‎the company’s shares closed on Monday.‎ Some new analysts also ‎started their coverage, with UBS’s analysts assigning the shares to “a Neutral” rating in a research note ‎to investors issued in late October. Meanwhile, Raymond James had raised its rating on AMGN to “an ‎Outperform” from the earlier “Mkt perform”, in a research note produced for clients October 26, 2020. ‎In addition, there was an upgrade from Truist on October 12, 2020. The rater changed AMGN from “a ‎Hold” to “a Buy”.

Get the hottest stocks to trade every day before the ‎market opens 100% free. Click here now. 

Is Amgen Inc. [NASDAQ:AMGN] a Good Buy Right Now?

It should be noted that AMGN ‎technical indicators for short, intermediate as well as long term progress have placed an overall ‎average of 88% as Sell. The average signal changed from 72% Sell in the last week and compares with ‎‎72% Sell in the past month. Data from Amgen Inc.’s Trend Spotter indicated that the signals were ‎Weakest. The stock current average is 2.57 million shares in the past 20 days and the short term ‎average signal indicates a 100% Sell. In the last 50 days, the average trading volume was 2.52 million ‎shares while the medium term average advocated for 100% Sell. The average long-term signal stands ‎at 50% Sell and the 100-day average volume stands at 2.66 million shares.‎‎


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


AMGN Price Performance

On Wall Street, Amgen Inc. [NASDAQ:AMGN] finished Monday’s ‎session up 0.32% at $223.65. The stock went up to $226.90 at the same session while its lowest single ‎day price was $223.03. In the last five days, it saw a fall of about -2.12%, Amgen Inc. shares dropped by ‎almost -7.23% since the beginning of the year. However, the share price has dropped to as low as -‎‎15.59% below its one year high. On 07/06/20, the company shares recorded $264.97, the highest ‎single-day price it has got to in the last 52-weeks and a 52-week low was seen on 03/23/20, the same ‎year at $177.05. The company’s shares have declined by -7.40% in the past year. The 50-day SMA ‎achieved is $227.52 while the 200-day SMA is $233.39. Volume gained to 1.5 million from 0.96 million in ‎the previous session.‎‎

Amgen Inc. [AMGN] Valuation Measures

Notably, Amgen Inc. [AMGN] stock can be ‎classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – ‎General companies to purchase soonest possible with the prevailing 12-month PE ratio of 18.03. The ‎measure means the stock is exchanging at a discount as compared to the 24.27x trailing earnings of the ‎industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 5.21 ‎PS value ratio is reported for the last one year of reported earnings. That is higher than the industry ‎average of 2.76 which means AMGN serve an attractive investment opportunity compared to its ‎competitors.‎‎

AMGN Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 222.15 level, and in case of violation of this particular level, it will cause more drop to ‎‎220.66 level. On the upper level, 228.40 is still the key resistance. The stock may increase to the ‎subsequent resistance at 226.02. The Relative Strength Index (RSI) pinned on the 14-day chart is 43.69, ‎implying a neutral technical stance while the MACD stands at -3.99, meaning price will decrease in the ‎next trading period. Percent R indicator moved to 70.52%, implying bearish price movement. ‎Stochastic %K at 25.52% suggest selling the stock.‎‎

What is the short interest in Amgen Inc.?

Short interest in the Amgen Inc. stock has surged, ‎increasing by 0.57 million shares to total 6.91 million shares on Dec 14, 2020. The interest had seen ‎shares on Nov 12, 2020 stand at 7.48 million, data from Yahoo Finance shows. The decrease of -8.25% ‎suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) ‎moved to while the shorted shares account for just 1.19% of the overall float for the stock.‎‎

Amgen Inc.’s Biggest Shareholders: Who Owns Amgen Inc. [AMGN]?

Filings by The ‎Vanguard Group, Inc. showed that the firm now holds a total of 45,176,984 shares or roughly 7.76% of ‎the outstanding AMGN shares. This means their shares have reduced by -738,612 from the 45,176,984 ‎the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Capital Research & ‎Management Co updated stake is worth $7,438,564,927. Details in the latest 13F filings reveal that ‎BlackRock Fund Advisors disposed off their -2.70% stake valued at $7,153,446,027 while SSgA Funds ‎Management, Inc. added theirs at $6,945,188,938. During the last quarter, BlackRock Fund Advisors ‎liquidated -892,381 of its shares in Amgen Inc. while SSgA Funds Management, Inc. bought 5,016,641 ‎shares. The PRIMECAP Management Co.’s holdings currently number 17,407,082 shares at ‎‎$3893093889.3. According to the firm’s last 13F report, Fidelity Management & Research Co shares in ‎the company at filing stood at 12,688,691 shares, roughly $2,817,396,950.‎‎

AMGN Earnings Forecast For The Current Quarter

Amgen Inc. [AMGN] is expected to report ‎weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company ‎expected revenues of $6.59B and an earnings per share of $3.41 for Dec 2020. Looking further ahead, ‎the company is expected to report revenue of $6.37B at an EPS of $4.21 for Mar 2021. The estimates ‎represent upside of 3.90% and 5.24% in the company’s revenue and earnings per share, respectively, ‎on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

AMGN Earnings Estimates For The Current ‎Year

For the financial year, Amgen Inc. [NASDAQ:AMGN] is expected to bring in revenue of ‎‎$25.38B. The returns are nearly $1.63 billion higher than the company’s actual revenue recorded in the ‎fiscal year 2019. In terms of EPS for the 2020, estimate put it at 16.17, higher than that of FY19 by $1.35. ‎Estimates put this year’s earnings growth at 9.10%, 5.10% for the next, and at an annual 6.65% over the ‎next 5-year period. As for sales, forecasts are for an increase of 6.90% in the current fiscal year and a ‎further 3.90% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Relmada Therapeutics Inc. (RLMD) stock is plunging in the current trading session; What’s going on?

In the current trading session, Relmada Therapeutics Inc. (RLMD) stock shares are plunging by -5.97%. The current trading price is at $23.62 in the...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

Related News

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%....

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam